Cachexia - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 73 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Cachexia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Cachexia - Pipeline Review, H2 2014', provides an overview of the Cachexia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cachexia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cachexia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Cachexia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cachexia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cachexia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cachexia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Cachexia Overview 8
Therapeutics Development 9
Pipeline Products for Cachexia - Overview 9
Pipeline Products for Cachexia - Comparative Analysis 10
Cachexia - Therapeutics under Development by Companies 11
Cachexia - Therapeutics under Investigation by Universities/Institutes 13
Cachexia - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Cachexia - Products under Development by Companies 16
Cachexia - Products under Investigation by Universities/Institutes 17
Cachexia - Companies Involved in Therapeutics Development 18
Plexxikon Inc. 18
BioLineRx, Ltd. 19
Neurocrine Biosciences, Inc. 20
Novartis AG 21
Aphios Corporation 22
Pfizer Inc. 23
Calzada Limited 24
Palatin Technologies, Inc. 25
Cytokinetics, Inc. 26
AVEO Pharmaceuticals, Inc. 27
Fountain Biopharma Inc. 28
Rhythm Pharmaceuticals 29
MI.TO. Technology S.r.L. 30
Cachexia - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
bimagrumab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
PF-06260414 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
DLN-101 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
relamorelin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
BL-5040 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
dronabinol - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
CK-2066260 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
PLX-4720 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
FB-704A - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules to Inversely Agonize Beta3-Adrenoreceptor for Cachexia, Metabolic Syndrome and Heart Failure - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
AV-380 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
AOD-9604 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Drug for Cachexia - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Drugs to Inhibit Activin Receptor for Cachexia - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecules to Modulate Melanocortin-4 Receptor for Cachexia - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Cachexia - Recent Pipeline Updates 59
Cachexia - Dormant Projects 63
Cachexia - Discontinued Products 64
Cachexia - Product Development Milestones 65
Featured News & Press Releases 65
Apr 01, 2013: Cytokinetics Initiates Phase I Clinical Trial Of CK-2127107 65
Jan 03, 2013: Alize Pharma Launches PREMAG Research Program 65
Oct 03, 2012: XBiotech Receives Fast Track Designation From FDA For Anti-Cachexia Drug Xilonix 66
Mar 13, 2012: Calzada Announces Positive Results Of AOD9604 In Cartilage And Muscle Repair Models 67
Jan 09, 2012: Ohr Pharmaceutical Receives US And European Composition Of Matter Patents 68
Sep 12, 2011: XBiotech Provides Early Results From True Human Antibody Therapy Clinical Study In Cachexia 68
Jul 20, 2011: Galapagos Initiates Proof-of-Mechanism Clinical Study Of Candidate Cachexia Drug GLPG0492 69
Dec 27, 2010: Vicus Initiates Phase II Trial To Evaluate VT-122 In Patients With Liver Cancer Receiving Nexavar 69
Dec 02, 2010: Galapagos Successfully Completes First-In-Human Trial Of GLPG0492 In Cachexia Patients 70
Jun 21, 2010: GTx Reports Ostarine Increased Lean Body Mass And Leg Press Strength In Head To Head Clinical Study 71
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 73
Disclaimer 73

List of Tables
Number of Products under Development for Cachexia, H2 2014 9
Number of Products under Development for Cachexia - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Cachexia - Pipeline by Plexxikon Inc., H2 2014 18
Cachexia - Pipeline by BioLineRx, Ltd., H2 2014 19
Cachexia - Pipeline by Neurocrine Biosciences, Inc., H2 2014 20
Cachexia - Pipeline by Novartis AG, H2 2014 21
Cachexia - Pipeline by Aphios Corporation, H2 2014 22
Cachexia - Pipeline by Pfizer Inc., H2 2014 23
Cachexia - Pipeline by Calzada Limited, H2 2014 24
Cachexia - Pipeline by Palatin Technologies, Inc., H2 2014 25
Cachexia - Pipeline by Cytokinetics, Inc., H2 2014 26
Cachexia - Pipeline by AVEO Pharmaceuticals, Inc., H2 2014 27
Cachexia - Pipeline by Fountain Biopharma Inc., H2 2014 28
Cachexia - Pipeline by Rhythm Pharmaceuticals, H2 2014 29
Cachexia - Pipeline by MI.TO. Technology S.r.L., H2 2014 30
Assessment by Monotherapy Products, H2 2014 31
Number of Products by Stage and Target, H2 2014 33
Number of Products by Stage and Mechanism of Action, H2 2014 35
Number of Products by Stage and Route of Administration, H2 2014 37
Number of Products by Stage and Molecule Type, H2 2014 39
Cachexia Therapeutics - Recent Pipeline Updates, H2 2014 59
Cachexia - Dormant Projects, H2 2014 63
Cachexia - Discontinued Products, H2 2014 64